TriangleNivolumab (NCT07689175)
Nivolumab trial for Hepatocellular Carcinoma (HCC) (NCT07689175). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with unresectable or metastatic hepatocellular carcinoma and Child-Pugh B7–8 liver function, without prior PD-1, PD-L1, or CTLA-4 therapy for advanced disease.
The idea: intravenous nivolumab and ipilimumab release immune brakes through PD-1 and CTLA-4. Favorable imaging responses trigger a treatment pause and an early scan. Doctors then decide whether to resume, hold, or stop treatment; progression can prompt another therapy. Researchers assess continued disease control and safety.
This phase 2 study plans 60 patients. David Hsieh leads at UT Southwestern in Dallas, the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.